Reliance and Work-Smart regulation



World Health Organization


Luther Gwaza PhD Technical Officer WHO/EMP/RHT/RSS, Email: gwazal@who.int



If you want to go quickly, go alone. If you want to go far, go together. ~ African proverb


All pharmaceutical products, including multisource products, should be used in a country **only after approval** by the national or regional authority. Regulatory authorities should require the documentation of a multisource pharmaceutical product to meet the following:

- GMP;
- Quality requirements; and
- Pharmaceutical product interchangeability




WHA Resolutions: WHA 67.20 (2014); WHA 67.21 (2014); WHA63.12 (2010)

IDEAL SITUATION



Medicines Regulation Process Flow


REALITY



Medicines Regulation Process Flow

Regulatory decision making






Defining Reliance and Recognition

Reliance: act whereby a regulatory authority in one jurisdiction may take into account/give significant weight to work performed by another regulator or other trusted institution in reaching its own decision.


Recognition: the routine acceptance of the regulatory decision of another regulator or other trusted institution. Recognition indicates that evidence of conformity with the regulatory requirements of country A is sufficient to meet the regulatory requirements of country B.



NRA capabilities




of children globally are immunized with WHO prequalified vaccines through the GAVI alliance





PEOPLE ON ANTIRETROVIRAL THERAPY ACROSS THE GLOBE ARE TREATED WITH WHO PREQUALIFIED GENERIC MEDICINES



How do WE get the quality assured product to these patients faster, and more efficient?

How do WE ensure continued supply of quality assured products post-registration?

Facilitated pathways to "transfer" regulatory information & knowledge



- **Sharing information** (assessment, inspection and testing results) that serve as basis for national decisions – avoiding duplication.
- Voluntary participation reference authorities, participating authorities and manufacturers/sponsors



PRINCIPLES





WHO collaborative procedure

Vaccines: 2004 Medicines: Started in 2012 **Diagnostics: Pilot 2019** Vector control: Pilot 2020

**CRP-lite

"SRA" collaborative

procedure

Initiated in 2015 **European Medicines** Agency (EMA) Medicines and Healthcare **Products Regulatory** Agency (MHRA) 20 African NRAs

Regional networks

Regulatory

DODWAS 19AD COEN

African Medicines ASEAN SIAHR Project Harmonization Project (AMRH) Caribbean Public Health

WHO Technical Report Series 996, 2016

WHO Expert Committee on Specifications for Pharmaceutical Preparations

Fiftleth report

http://apps.who.int/iris/bitstream/handle/10665/25533 8/9789241209960-eng.pdf?sequence=1

Annex 8

Collaborative procedure between the World Health Organization (WHO) Prequalification Team and national regulatory authorities in the assessment and accelerated national registration of WHO-prequalified pharmaceutical products and vaccines

1.	Definitions			
2.	Backgro	und information	265	
3.	3. Principles of collaboration		267	
4.	 Steps in the collaboration for national registration of a pharmaceutical product or a vaccine 			
 Collaboration mechanisms for post-prequalification and/or post-registration variations 		279		
6.	 Withdrawals, suspensions or delistings of prequalified pharmaceutical products or vaccines and national deregistrations 			
References				
Appendix 1		National regulatory authority participation agreement and undertaking for national regulatory authority focal point(s)	282	
Appendix 2		Consent of WHO prequalification holder for WHO to share information with the national regulatory authority confidentially under the Procedure	292	
Appendix 3		Expression of interest to national regulatory authority (NRA) in the assessment and accelerated national registration, acceptance by NRA and notification of Procedure outcomes	295	
Appendix 4		Report on post-registration actions in respect of a product registered under the Procedure	303	

Published guidelines

WHO Technical Report Series 1010, 2018

WHO Expert Committee on Specifications for Pharmaceutical Preparations

Fifty-second report

http://apps.who.int/iris/bitstream/handle/10665/272452/978 9241210195-eng.pdf?ua=1



Annex 11

Collaborative procedure in the assessment and accelerated national registration of pharmaceutical products and vaccines approved by stringent regulatory authorities

1.	Background information	272
2.	Glossary	273
3.	Principles of collaborative procedure	275
4.	Medicines	278
5.	Collaboration mechanisms for management of post-registration	
	variations	284

Published guidelines

WHO Technical Report Series 1010, 2018

WHO Expert Committee on Specifications for Pharmaceutical Preparations

Fifty-second report

http://apps.who.int/iris/bitstream/handle/10665/272452/978 9241210195-eng.pdf?ua=1

Annex 9


Guidance on good practices for desk assessment of compliance with good manufacturing practices, good laboratory practices and good clinical practices for medical products regulatory decisions

Background			273
1.	Introduction		
2.	Aim and objectives of the guidance		
3.	. Scope of the guidance		276
4.	Glo	ssary	277
5.	Essential elements of desk assessment		279
	5.1	High-level support and cooperation	279
	5.2	Commonality of quality management systems in inspectorates	280
	5.3	Convergent standards of good practices	280
	5.4	Reliability and accuracy of information	281
	5.5	Management tools to support consistent and objective assessment	281
	5.6	Risk-based assessment of available information	281
	5.7	Mutual trust and confidence among inspectorates	282
	5.8	Quality assurance of the desk assessment process	282
	5.9	Communication of assessment outcomes	282


Published guidelines

Concept of collaborative registrations (Reliance) To support the national registrations, regulators can benefit from already organized scientific assessments and inspections, if


- Having access to regulatory expertise from trusted party (complete assessment and inspection reports)
- Having the same product
- Having same essential technical data
- Understanding validity of B/R for local environment**
- National legislation and sovereignty are not affected
- Respect confidentiality of commercially sensitive information
- Manage properly regulatory follow-up



IDEAL SITUATION - WITH FACILITATED PATHWAYS



Medicines Regulation Process Flow





(a) # of products retained a approved, 21 # of facilities inspected & approved based on reliance (record line)


decisions by others), work-sharing, & centralised procedure (c) of reviewed multi-country trials, (d) utilisation of central states of the sta

Shared regulatory approach A modern regulator

harmonization cooperation efficient work-sharing **recognition** joint risk-management effective outcome-oriented **collaboration** Access to safe, effective, good quality and affordable essential medicines & health technologies

(1) Time to approval; (2) incidence of SSFFCs, (3) # of certified suppliers per essential medicine, (4) compliance rate to GMP & GxP standards, (5) # of reported ADRs per 100,000 population

(a) # of submitted & approved products , (b) # of approved facilities, (c) # of submitted & approved clinical trials, (d) % of samples tested, (e) # of ADRs/product related reports



Policy & legal framework, human resources, financial resources, political support / will, infrastructure and equipment

Source: L Gwaza & G.N. Mahlangu (2015). Business Plan for the African Medicines Agency



Laboratory Testing Services

- WHO National Control Laboratory Network for Biologicals 2017
- Use of WHO PQ'ed laboratories for testing of pharmaceuticals



Lessons learnt with respect to facilitated pathways – for NRAs

Barriers to reliance

- 1. Legislative prohibitions ???
- 2. Backlog in reviews (use of FIFO)
- Lack of tools for recognition, reliance or work sharing (one approach for all applications)
- 4. Change management

Key enablers for reliance

- 1. Enabling laws
- Risk based approach to registration and Inspections
- 3. Guidelines
- 4. Procedures to guide staff
- 5. Staff awareness on reliance approaches
- 6. Communication (internal and external)





"At a time in which medical product manufacturing is truly a global enterprise, there is much to be gained by partnering with regulatory counterparts to reduce duplicative efforts and maximize global resources while realizing the greatest bang for our collective inspectional buck. By partnering with these countries we can create greater efficiencies and better fulfil our public health goals, relying on the expertise of our colleagues and refocusing our resources on inspections in higher risk countries." FDA Commissioner Scott Gottlieb, M.D. October 31, 2017.



This is the Regulator's Dilemma!!...

"The need to maintain such a delicate balance by applying **appropriate standards** that are **scientifically justified** and **risk proportionate** to **protect public** <u>health</u> while ensuring <u>economic</u> <u>and industrial interests</u> are not hindered".



The Future



